CHKB-AS1 enhances proliferation and resistance to NVP-BEZ235 of renal cancer cells via regulating the phosphorylation of MAP4 and PI3K/AKT/mTOR signaling

Abstract Targeted therapy is pivotal in renal carcinoma treatment, and the dual-inhibitor NVP-BEZ235 has emerged as a promising candidate in preliminary studies. Its effectiveness against renal carcinoma and the mechanisms underlying potential resistance, however, warrant further exploration. This s...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Xinglin Chen, Tongtong Zhang, Xiaohan Ren, Yuang Wei, Xu Zhang, Xinyue Zang, Xiran Ju, Chao Qin, Dongliang Xu
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	BMC 2023-12-01
Serie:	European Journal of Medical Research
Ämnen:	ccRCC NVP-BEZ235 Drug resistance Oncology Urology
Länkar:	https://doi.org/10.1186/s40001-023-01558-w
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!